Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients

Melanoma and Skin Cancer

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

JAMA Dermatol.

Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T

doi: 10.1001/jamadermatol.

Melanoma and Skin Cancer

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Eur J Cancer

Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X

doi: 10.1016/j.ejca.2021.07.018

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

Melanoma and Skin Cancer

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Eur J Cancer

Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y

doi: 10.1016/j.ejca.2021.08.034

COMMENTED

Melanoma and Skin Cancer

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

JAMA Oncol.

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD

doi: 10.1001/

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Melanoma and Skin CancerImmunotherapyT Cells

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

Front Immunol.

Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt MV, Bürdek M, Berking C, Prinz JC

doi: 10.3389/fimmu.

Melanoma and Skin CancerImmunotherapy

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Nat Med.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B

doi: 10.1038/nm.4466.

Melanoma and Skin Cancer

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

Semin Oncol

Pala L, Conforti F, Saponara M, De Pas T, Giugliano F, Omodeo Salè E, Jemos C, Marco R, Andrea A, Quaglino P, Fava P, Fierro MT, Queirolo P

doi: 10.1053/j.seminoncol.2020.07.010

Related content

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19